Simon Mensah Ametamey

USPTO Granted Patents = 16 (Patent Applications = 5)

CIPO Patents = 6 (Patent Applications = 2)

EPO Patents = 11 (Patent Applications = 10)

Average Co-Inventor Count = 5.3

ph-index = 3

Forward Citations = 20(Granted Patents)

Location History:

Zürich, CH (2014)
Zurich, CH (2013 - 2024)

Company Filing History:

Hoffmann-la Roche Inc.

Eidgenoessische Technische Hochschule Zuerich

patents

5. 1 out of 378

Bayer Pharma Aktiengesellschaft

Eidgenössische Technische Hochschule Zürcih

where one patent can have more than one assignee

Years Active: 2013-2024

Loading Chart...

16 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12180196 - Azetidine-substituted pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 (2024-12-31),

2. 12071420 - Pyridine and pyrazine compounds as inhibitors of cannabinoid receptor 2 (2024-08-27),

3. 11999710 - Radiolabeled cannabinoid receptor 2 ligand (2024-06-04),

4. 11655243 - Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists (2023-05-23),

5. 10973936 - F-saccharide-folates (2021-04-13),

6. 10961246 - F-labelled folates as PET radiotracers (2021-03-30),

7. 10377756 - F-labelled folates (2019-08-13),

8. 10357576 - 18F-labelled folate/antifolate analogues (2019-07-23),

9. 10322195 - [object Object] (2019-06-18),

10. 10227308 - Radiolabeled cannabinoid receptor 2 ligand (2019-03-12),

11. 9771368 - [object Object] (2017-09-26),

12. 9315506 - 18F-labelled folates (2016-04-19),

13. 9295739 - Folate conjugates of albumin-binding entities (2016-03-29),

14. 8674110 - Pyridylacetylenes for use as radiotracers and imaging agents (2014-03-18),

15. 8557776 - [object Object] (2013-10-15),

Title: Simon Mensah Ametamey: A Trailblazer in Pharmaceutical Innovations

Introduction

Simon Mensah Ametamey is a distinguished inventor based in Zurich, Switzerland, with a remarkable portfolio comprising 13 patents. His work primarily focuses on the development of novel compounds that can serve as effective medicaments, particularly in the fields of cannabinoids and radiopharmaceuticals.

Latest Patents

Among his notable inventions, Simon's latest patents include "Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists." This innovation introduces a compound of formula (I), where A, A', and R-R' are specifically defined in the accompanying description and claims. It is noteworthy that this compound has potential medical applications. Another significant patent is "F-saccharide-folates," which pertains to new F-folate radiopharmaceuticals. In this invention, the F isotope is linked through a prosthetic group with a saccharide nature, enhancing its utility in diagnosing and monitoring cancer as well as inflammatory and autoimmune diseases.

Career Highlights

Simon Mensah Ametamey has made significant contributions during his career, having worked with prominent companies such as Merck & Cie and Hoffmann-La Roche Inc. His extensive expertise in pharmaceuticals has played a pivotal role in advancing the science behind therapeutic solutions.

Collaborations

Throughout his career, Simon has collaborated with esteemed professionals in the field, including Rudolf Moser and Viola Groehn. These collaborations have allowed him to harness collective knowledge and drive innovation in his research endeavors.

Conclusion

Simon Mensah Ametamey stands out as a pivotal figure in pharmaceutical innovation, with an impressive array of patents that underline his commitment to developing groundbreaking solutions. His innovative spirit continues to pave the way for advancements in medicinal chemistry and beyond.

This text is generated by artificial intelligence and may not be accurate.